Scientific Symposium & Working Sessions

Saudi GU Working Group Annual Scientific Sessions: Advancing Multidisciplinary Care in Genitourinary Malignancies

The Steering Committee of the Saudi Genitourinary (GU) Working Group cordially invites oncologists, urologic surgeons, and healthcare practitioners across the Kingdom to the official Scientific Working Sessions and Multidisciplinary Symposium. This landmark event unifies leading clinical experts to discuss therapeutic evolutions, localized referral pathways, and modern patient management.
Saudi GU Working Group Scientific Meeting Official Invitation - You're Invited
Figure 1: Official Saudi GU Working Group Symposium invitation banner, convened under scientific partnership with the Saudi Uro-Oncology Group.
Date & Schedule Tuesday, 17 June 2025
Location Riyadh, Saudi Arabia
Accreditation CME Accredited Event
Target Audience Urologists & Oncologists

1. About the Scientific Meeting

Genitourinary cancers represent a significant healthcare priority across the Gulf region. In response to recent landmark data in systemic immunotherapies, targeted radioligands, and antibody-drug conjugates (ADCs), the Saudi Genitourinary Working Group convenes this full-day symposium to bridge emerging global science with routine clinical practice across Saudi institutions.

The program gathers department chairs, senior consultants, and fellows from tertiary centers including King Faisal Specialist Hospital & Research Centre (KFSH&RC), King Fahd Medical City (KFMC), King Fahd Specialist Hospital Dammam, and Ministry of Defense Health Services (MODHS).

2. Core Scientific Agenda & Thematic Sessions

Session 01 • Urothelial Carcinoma

Transforming Urothelial Cancer Care

Focus: Implementation of first-line Enfortumab Vedotin plus Pembrolizumab (EV-302), sequencing post-platinum maintenance immunotherapy, and quality indicators in Transurethral Resection of Bladder Tumor (TURBT).
Session 02 • Prostate Cancer

Precision Medicine & Radioligands

Focus: Earlier integration of Lutetium-177 vipivotide tetraxetan (PSMAfore data), PARP inhibitor combinations in BRCA-altered metastatic castration-resistant disease, and treatment intensification in mHSPC.
Session 03 • Healthcare Policy

National Referral Checklists & MDTs

Focus: Establishing rapid-access hematuria referral criteria, overcoming inter-facility bottlenecks, and standardizing multidisciplinary tumor boards across regional health clusters.
Session 04 • Workshops

Challenging Tumor Board Case Debates

Focus: Interactive cross-table discussions featuring real-world complex patient scenarios, radiation-sparing modalities, and oligometastatic management dilemmas.

3. Official Invitation & Program Brochure

The formal meeting invitation detailing the scientific agenda, distinguished keynote speakers, and session timings is available for direct download below:

Official Invitation & Program Guide (PDF)

Download the high-resolution invitation circular and comprehensive conference timetable for the June 17th working sessions.

Download Invitation PDF